What is it about?

This paper delves into the study of a group of compounds known as 2,5-Diketopiperazines (DKPs), which are commonly found in various natural sources like bacteria, fungi, and marine organisms. These compounds are particularly interesting to researchers because they have shown promise in fighting cancer. The review covers extensive research conducted from 1997 to 2022, highlighting the anti-cancer potential of both natural and synthetic DKPs. The authors discuss how modifications to the DKP structure have enhanced their effectiveness against cancer cells by influencing how these cells grow and survive. They have also explored how these compounds can be optimized to target cancer cells more effectively while minimizing side effects, which is a significant challenge in current cancer treatments. By examining the chemical structure of DKPs and their variants, the paper provides insights into how these compounds interact at the molecular level with cancer cells. This understanding could lead to the development of new anticancer drugs that are more effective and have fewer side effects than existing therapies. In summary, the research presented in this paper offers hopeful avenues for future cancer treatments through the detailed study of DKPs, shedding light on their potential as a basis for developing new anticancer agents.

Featured Image

Why is it important?

The unique aspects of this work involve a comprehensive and detailed analysis of 2,5-Diketopiperazine (DKP) derivatives, focusing on their potential as anticancer agents. This paper is a valuable resource for researchers in medicinal chemistry, especially those focusing on anticancer drug design.


From a personal perspective, this paper on 2,5-Diketopiperazines (DKPs) as anticancer agents was both enlightening and promising. Compiling and analyzing decades of research on DKPs, provides a robust foundation for understanding their potential in cancer treatment. What stood out to me was how small chemical changes can significantly enhance their therapeutic efficacy. This aspect is particularly exciting as it opens up possibilities for designing more effective drugs with fewer side effects—a critical advancement in cancer therapy. Moreover, the emphasis on improving the pharmacokinetics and specificity of these compounds addresses a significant challenge in drug development. The potential to create DKP-based drugs that are not only effective but also have a better safety profile could represent a major step forward in oncological treatments. Overall, I wrote this paper not only to contribute to the scientific community by providing a thorough analysis of DKP derivatives but also to inspire further research and development in this area. It’s a testament to the complexities and possibilities within the field of medicinal chemistry, and it highlights the innovative approaches that could lead to breakthroughs in cancer treatment.

Professor Bahaa Elgendy
Washington University in Saint Louis

Read the Original

This page is a summary of: 2,5-Diketopiperazines (DKPs): Promising Scaffolds for Anticancer Agents, Current Pharmaceutical Design, March 2024, Bentham Science Publishers,
DOI: 10.2174/0113816128291798240201112916.
You can read the full text:



The following have contributed to this page